Literature DB >> 18221479

Metabolism of (4-phenoxyphenylsulfonyl) methylthiirane, a selective gelatinase inhibitor.

Giuseppe Celenza1, Adriel Villegas-Estrada, Mijoon Lee, Bill Boggess, Christopher Forbes, William R Wolter, Mark A Suckow, Shahriar Mobashery, Mayland Chang.   

Abstract

(4-Phenoxyphenylsulfonyl)methylthiirane (compound 1) is a highly selective and potent inhibitor of gelatinases that shows considerable promise in animal models for cancer and stroke. The metabolism of compound 1 was investigated in mice, following intraperitoneal administration at 100 mg/kg. Eight metabolites were identified in plasma and urine. The primary routes of metabolism of 1 were hydroxylation at the para-position of the terminal phenyl ring, hydroxylation at the alpha-methylene to the sulfonyl, which lead to the generation of a sulfinic acid, and cysteine conjugation of the thiirane ring. The cysteine adducts arose through addition of glutathione to the thiirane ring. The molecule is extensively metabolized and

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18221479     DOI: 10.1111/j.1747-0285.2008.00632.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  11 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 3.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

4.  Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.

Authors:  Kushalava Reddy Yempalla; Gurunadham Munagala; Samsher Singh; Asmita Magotra; Sunil Kumar; Vikrant Singh Rajput; Sonali S Bharate; Manoj Tikoo; G D Singh; Inshad Ali Khan; Ram A Vishwakarma; Parvinder Pal Singh
Journal:  ACS Med Chem Lett       Date:  2015-08-31       Impact factor: 4.345

5.  Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.

Authors:  Mijoon Lee; Masahiro Ikejiri; Dennis Klimpel; Marta Toth; Mana Espahbodi; Dusan Hesek; Christopher Forbes; Malika Kumarasiri; Bruce C Noll; Mayland Chang; Shahriar Mobashery
Journal:  ACS Med Chem Lett       Date:  2012-05-02       Impact factor: 4.345

6.  Exploration of mild copper-mediated coupling of organotrifluoroborates in the synthesis of thiirane-based inhibitors of matrix metalloproteinases.

Authors:  Sebastian A Testero; Renee Bouley; Jed F Fisher; Mayland Chang; Shahriar Mobashery
Journal:  Bioorg Med Chem Lett       Date:  2010-12-29       Impact factor: 2.823

7.  Synthesis, kinetic characterization and metabolism of diastereomeric 2-(1-(4-phenoxyphenylsulfonyl)ethyl)thiiranes as potent gelatinase and MT1-MMP inhibitors.

Authors:  Major Gooyit; Mijoon Lee; Dusan Hesek; Bill Boggess; Allen G Oliver; Rafael Fridman; Shahriar Mobashery; Mayland Chang
Journal:  Chem Biol Drug Des       Date:  2009-10-12       Impact factor: 2.817

8.  A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition.

Authors:  Mijoon Lee; Giuseppe Celenza; Bill Boggess; Jennifer Blase; Qicun Shi; Marta Toth; M Margarida Bernardo; William R Wolter; Mark A Suckow; Dusan Hesek; Bruce C Noll; Rafael Fridman; Shahriar Mobashery; Mayland Chang
Journal:  Chem Biol Drug Des       Date:  2009-02       Impact factor: 2.817

Review 9.  Matrix metalloproteinases, T cell homing and beta-cell mass in type 1 diabetes.

Authors:  Alexei Y Savinov; Alex Y Strongin
Journal:  Vitam Horm       Date:  2009       Impact factor: 3.421

10.  Metabolism of the Selective Matrix Metalloproteinase-9 Inhibitor (R)-ND-336.

Authors:  Charles Edwin Raja Gabriel; Trung T Nguyen; Emanuele Marco Gargano; Jed F Fisher; Mayland Chang; Shahriar Mobashery
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.